Royalty Report: Medical, Cancer, Diagnostic – Collection: 27476


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Medical
  • Cancer
  • Diagnostic
  • Device
  • Test/Monitoring

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27476

License Grant
The Licensor granted the Licensee, a long-time partner,  the exclusive rights to sell the products in China provided that the Licensee achieves local regulatory approvals within a 3-year period and does not export from China.
License Property
The Licensor is developing, testing and commercializing its non-invasive lung cancer risk test. The Electro Pulmonary Nodule Scan is a bioconductance measurement method to evaluate the risk of lung cancer in patients with lesions of the lung in well-controlled clinical trials.

The EPN Scan device is designed to provide further information on whether a lung legion may be cancerous after detection by CT Scan.

Field of Use
In February 2014, the Chinese licensee received approval to manufacture, but not market or sell, the device in China as a lung cancer risk stratification device.  On March 15, 2015 the licensee entered clinical trials at two prominent hospitals for the purpose of seeking approval to market and sell the EPN Scanner in China.

IPSCIO Record ID: 7557

License Grant
The Licensee has the right to the worldwide, exclusive use of certain patents and patents pending and related technology in its medical devices and other products for an indefinite term.
License Property
EPN Scan is a non-invasive lung cancer diagnostic test (the Electro Pulmonary Nodule Scan, EPN Scan, or our Test. The EPN Scan assists in evaluating the risk associated with a CT finding in the lung that is suspicious for cancer.
The Agreement, as amended, addresses certain mechanical aspects of the hardware and a portion of the software of the EPN Test.

Specifically, the Licensee has Licensed certain design features of the EPN Scan including the probe and platform, which are described in U.S. Patent numbers 7,536,220, 7,542,796, and 7,937,139.

Field of Use
The Licensee has Licensed certain design features of the EPN Scan including the probe and platform.

IPSCIO Record ID: 89818

License Grant
The company entered into a license agreement with a party pursuant to which the company granted the party an exclusive license to manufacture, sell and distribute LuViva in Taiwan, Brunei, Darussalam, Cambodia, Laos, Myanmar, Philippines, Singapore, Thailand, and Vietnam.   The party was already our exclusive distributor in China, Macau and Hong Kong, and the license extends to manufacturing in those countries as well. Under the terms of the license agreement, once the party is capable of manufacturing LuViva in accordance with ISO 13485 for medical devices, the Licensee will pay a royalty of the distributor price (subject to a discount under certain circumstances), whichever is higher, per disposable distributed within the Licensee’s exclusive territories.
License Property
LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.  LuViva provides a less invasive and painless alternative to conventional tests for cervical cancer screening and detection.
Field of Use
This agreement pertains to the medical industry relating to medical devices for detection of cancers.

IPSCIO Record ID: 363938

License Grant
The parties agreed to terminate all prior agreements and replace with a worldwide royalty bearing license agreement for Nodify XL2 test for 15 years from the first commercial sale, ending in 2034.
License Property
Nodify XL2 is a blood-based lung cancer test to assess the risk of lung cancer to help identify the most appropriate treatment pathway.
Field of Use
Field of use is for the testing related to lung cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.